This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Spectrum Pharma: Guessing Q3 Fusilev Sales

Stocks in this article: SPPI

HENDERSON, Nev. ( TheStreet) --September sales of the Spectrum Pharmaceuticals' (SPPI) colon cancer drug Fusilev totaled $31.5 million in September, according to an estimate compiled by healthcare research firm Wolters Kluwer Wednesday.

For the three months that make up the third quarter, Fusilev estimated sales totaled $99 million. July sales were $31.8 million, August sales $35.4 million, according to Wolters Kluwer.

How accurately the Fusilev sales estimates track actual sales reported by Spectrum is a guessing game. In the second quarter, Spectrum reported Fusilev sales of $56.6 million, short of the $97 million suggested by the Wolters Kluwer monthly sales data.

Wolters Kluwer tracks gross sales of Fusilev while Spectrum reports net sales that subtract discounts, rebates and other financial incentives to doctors. As previously reported, Spectrum increased Fusilev discounting in the June quarter, which lowered the effective net selling price of Fusilev.

If the same rough gross-to-net discounting trend continued in the third quarter, Spectrum could report slightly higher Fusilev sales of around $57 million.

With so few analysts covering Spectrum, generating consensus estimates is difficult. Roth Capital Partners' Joe Pantginis lowered his third-quarter Fusilev sales estimate to $50.1 million from $58.2 million. RBC Capital's Adnan Butt is forecasting $59.4 million in Fusilev sales for the quarter.

Fusilev sales comprised 86% of Spectrum's second-quarter revenue so how well the drug performs is vitally important to the company's future growth. Spectrum continues to benefit from supply shortages of leucovorin, a cheaper, generic equivalent to Fusilev.

Spectrum shares were up 1% to $11.36 in early Wednesday trading. The stock is down 20% for the year despite a strong returns for the biotech sector, generally.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs